Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2.

Abstract

Several groups have used high doses of interleukin-2 (IL-2), achieving a significant rate of responses in patients with acute myelogenous leukemia (AML). These results have mainly been observed in AML patients with limited disease (bone marrow blasts < 25%), but this therapy is associated with significant toxicity which is dose-related. In this report we describe a patient with AML in whom conventional chemotherapy had achieved partial remission. This patient received subcutaneously intermediate doses of IL-2 (12 x 10(6)/m2/week) and achieved complete remission which was maintained for eleven months. The side effects of IL-2 were mild. The results of this report document the antileukemic effect of IL-2 in AML with limited disease as well as the efficacy of subcutaneous maintenance treatment for prolonged periods.

• Authors: M Speletas, K Ritis, G Bourikas
• Journal: Haematologica (Haematologica) 1996 Jul-Aug Vol. 81 Issue 4 Pg. 346-8 ISSN: 0390-6078 [Print] Italy
• PMID: 8870381 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interleukin-2
• Recombinant Proteins

Topics

• Humans
• Injections, Subcutaneous
• Interleukin-2 (administration & dosage)
• Leukemia, Myeloid, Acute (drug therapy)
• Male
• Middle Aged
• Recombinant Proteins (administration & dosage)